Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 1/20 | 0.95 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 2/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | EIF4E | P06730 | 2/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29689260 | 0.96 | DCPS (0.92) | DCPSTGM2FUT5KRASNT5E | |
| SCHEMBL29824509 | 0.86 | DCPS (0.72) | DCPSEIF4E | |
| SCHEMBL29466648 | 0.85 | DCPS (0.72) | DCPSEIF4E | |
| SCHEMBL29413985 | 0.85 | DCPS (0.71) | DCPSTGM2FUT5KRASNT5E | |
| SCHEMBL29438538 | 0.83 | DCPS (0.72) | DCPSEIF4E | |
| SCHEMBL29390254 | 0.83 | DCPS (0.70) | DCPSEIF4E | |
| SCHEMBL18769114 | 0.82 | TGM2 (0.85) | DCPSTGM2FUT5KRASNT5E | |
| SCHEMBL21067722 | 0.82 | TGM2 (0.85) | DCPSTGM2FUT5KRASNT5E | |
| SCHEMBL851357 | 0.82 | TGM2 (0.85) | DCPSTGM2FUT5KRASNT5E | |
| SCHEMBL29429843 | 0.82 | TGM2 (0.85) | DCPSTGM2FUT5KRASNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3169 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107144-A1 | RNA SEQUENCE FOR EXPRESSING PROTEIN IN CARDIOMYOCYTES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-05-21 | — | — | WO | claimed |
| CN-122055140-A | Pharmaceutical composition containing nucleic acid construct and medical application thereof | 上海瑞宏迪医药有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260124231-A1 | OLIGONUCLEOTIDE ENCODING A TISSUE INHIBITOR OF METALLOPROTEASES PROTEIN FOR MEDICAL USE IN MAMMALS | UNIV TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2026-05-07 | — | — | US | claimed |
| US-20260110033-A1 | MULTIPLEX CELLULAR REFERENCE MATERIALS | LGC CLINICAL DIAGNOSTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4728076-A1 | METHOD FOR STABILIZING RNA | Pfizer Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260061042-A1 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | PFIZER (US) | 2026-03-05 | — | — | US | claimed |
| EP-4673553-A2 | METHODS AND DEVICES FOR PREPARING CAPPED RNA BY FED-BATCH TRANSCRIPTION | Ribopro B.V. (NL) | 2026-01-07 | — | — | EP | claimed |
| EP-4661900-A1 | IMMUNE EFFECTOR CELLS STABLY AND TRANSIENTLY EXPRESSING NUCLEIC ACIDS | BIONTECH CELL & GENE THERAPIES GMBH (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4658679-A1 | OLIGONUCLEOTIDE ENCODING A TISSUE INHIBITOR OF METALLOPROTEASES PROTEIN FOR MEDICAL USE IN MAMMALS | Eberhard Karls Universität Tübingen, Medizinische Fakultät (DE) | 2025-12-10 | — | — | EP | claimed |
| EP-4644552-A1 | POLYNUCLEOTIDE MOLECULE FOR PREVENTING OR TREATING HPV INFECTION-RELATED DISEASES | Rinuagene Biotechnology Co., Ltd. (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2022241045-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| EP-4076647-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac AG (DE) | 2022-10-26 | — | — | EP | claimed |
| WO-2022219606-A1 | POLYNUCLEOTIDES CAPABLE OF ENHANCED PROTEIN EXPRESSION AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2022-10-20 | — | — | WO | claimed |
| US-20220288199-A1 | Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers | SANOFI (FR) | 2022-09-15 | — | — | US | claimed |
| CN-114941018-A | Method for synthesizing cap analogue of cap1 | 翌圣生物科技(上海)股份有限公司 | 2022-08-26 | — | — | CN | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| WO-2022125968-A1 | POLYNUCLEOTIDES, COMPOSITIONS, AND METHODS FOR GENOME EDITING INVOLVING DEAMINATION | INTELLIA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| CN-114517211-A | Immune cell culture and specific load activation method based on liposome-delivered mRNA | 苏州班凯基因科技有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-108473956-B | Methods of enhancing in vivo persistence and efficacy of exogenously administered T cells, genetically modified T cells and methods of use | 北昊干细胞与再生医学研究院有限公司 | 2022-04-05 | — | — | CN | claimed |
| WO-2022036858-A1 | NOVEL 5'CAP ANALOG HAVING CAP2 STRUCTURE AND PREPARATION METHOD THEREFOR | 深圳市瑞吉生物科技有限公司 | 2022-02-24 | — | — | WO | claimed |